SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals informs about audio recording of analyst meet

06 Jun 2022 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, and further to its letter dated 02nd June 2022 regarding intimation of Investors/ Analyst conference call held on today, 06th June, 2022, on the Audited Financial Results of the Company for the fourth quarter and financial year ended 31st March, 2022, SMS Pharmaceuticals has informed that the audio recording of the said call has been uploaded on the Company’s website. This can be accessed via the following link. https://smspharma.com/wp-content/uploads/2022/06/Q4FY22-Concall-AudioTranscript.mp3.

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×